Basel, Switzerland, Wednesday, September 25, 2024 – CIS BIOPHARMA, a leading oncology-focused biotech company, presented its innovative oncology pipeline to a distinguished audience of industry leaders, researchers, and investors at the 24th Sachs Biotech in Europe Forum.
The Forum, organized by Sachs Associates, took place at the Mövenpick Hotel in Basel, providing an ideal setting for dynamic interactions among industry experts. The event featured high-caliber panels discussing cutting-edge industry trends, including the application of artificial intelligence in drug development.
Christoph Schäfer, CEO of CIS BIOPHARMA, stated: «The Sachs Forum offered an exceptional platform to highlight our innovative antibody-drug conjugates and radioligand therapies. We were greatly encouraged by the level of engagement and interest in our pipeline.»
Ruggero della Bitta, CMO, remarked: «This event underscored the industry’s focus on novel targets and modalities to advance targeted therapies with improved patient outcomes. The past 18 months have marked a significant shift for ADCs and radioligands, which we anticipate will become standard of care in oncology. We have identified a novel target to develop a first-in-class therapy with the potential to become the standard of care for small cell lung cancer.»
CIS BIOPHARMA’s participation in Sachs 2024 reaffirms its dedication to advancing cancer treatments and collaborating with leaders in the biotech community to enhance patient outcomes.
About CIS BIOPHARMA AG
CIS BIOPHARMA is a privately-owned, Basel-based oncology company developing next-generation immuno-conjugates to address aggressive forms of tumors. The company’s product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs, that selectively target tumor cells. CIS BIOPHARMA is committed to helping cancer patients live longer and better lives.